Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC
- PMID: 39522531
- DOI: 10.1016/S1473-3099(24)00688-1
Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC
Conflict of interest statement
AK, IN, SP, and MH conducted contract research (testing of vaccinee sera for neutralising activity against SARS-CoV-2) for Valneva, unrelated to this work. GMNB served as an Advisor for Moderna, SP served as an Advisor for BioNTech, and AD-J served as an Advisor for Pfizer, unrelated to this work. All other authors declare no competing interests. AD-J acknowledges funding by the European Social Fund (ZAM5-87006761) and, together with GMNB, by the Ministry for Science and Culture of Lower Saxony (Niedersächsisches Ministerium für Wissenschaft und Kultur; 14-76103-184, COFONI Network, project 4LZF23). SP acknowledges funding by the EU project UNDINE (grant agreement number 101057100), the COVID-19-Research Network Lower Saxony (COFONI) through funding from the Ministry of Science and Culture of Lower Saxony in Germany (14-76103-184, projects 7FF22, 6FF22, and 10FF22) and Bundesministerium für Bildung und Forschung (COVIM, 01KX2121). The funding sources had no role in the design and execution of this work, the writing of the manuscript, or the decision to submit for publication. The authors did not receive payment by a pharmaceutical company or other agency to write this publication. The authors were not precluded from accessing data in the study, and they accept responsibility to submit for publication.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous